Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and Applied …, 2023 - journals.sagepub.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
[HTML][HTML] Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review
Y Zhao, M Guo, D Li, W Xu, C Pan, C He… - Clinical and Applied …, 2023 - ncbi.nlm.nih.gov
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m 2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical & Applied …, 2023 - search.ebscohost.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m²) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and applied …, 2023 - pubmed.ncbi.nlm.nih.gov
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m 2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.
Y Zhao, M Guo, D Li, W Xu, C Pan, C He… - Clinical and Applied …, 2023 - europepmc.org
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m 2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.
Y Zhao, M Guo, D Li, W Xu, C Pan, C He… - Clinical and Applied …, 2023 - europepmc.org
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m 2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …